NO20076187L - Fast, transdermalt, terapeutisk system omfattende UV-absorber - Google Patents

Fast, transdermalt, terapeutisk system omfattende UV-absorber

Info

Publication number
NO20076187L
NO20076187L NO20076187A NO20076187A NO20076187L NO 20076187 L NO20076187 L NO 20076187L NO 20076187 A NO20076187 A NO 20076187A NO 20076187 A NO20076187 A NO 20076187A NO 20076187 L NO20076187 L NO 20076187L
Authority
NO
Norway
Prior art keywords
absorber
therapeutic system
layer
transdermal therapeutic
tts
Prior art date
Application number
NO20076187A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Langguth
Stefan Bracht
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20076187L publication Critical patent/NO20076187L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20076187A 2005-05-02 2007-11-30 Fast, transdermalt, terapeutisk system omfattende UV-absorber NO20076187L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05009579A EP1719504A1 (de) 2005-05-02 2005-05-02 Festes transdermales therapeutisches System mit UV-Absorber
PCT/EP2006/003959 WO2006117139A2 (de) 2005-05-02 2006-04-28 Festes transdermales therapeutisches system mit uv-absorber

Publications (1)

Publication Number Publication Date
NO20076187L true NO20076187L (no) 2007-11-30

Family

ID=34981458

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076187A NO20076187L (no) 2005-05-02 2007-11-30 Fast, transdermalt, terapeutisk system omfattende UV-absorber

Country Status (26)

Country Link
EP (2) EP1719504A1 (pt)
JP (2) JP5360877B2 (pt)
KR (2) KR101351161B1 (pt)
CN (2) CN108969507A (pt)
AR (1) AR055927A1 (pt)
AU (1) AU2006243442A1 (pt)
BR (1) BRPI0611087A2 (pt)
CA (1) CA2605112C (pt)
CR (1) CR9483A (pt)
CY (1) CY1115757T1 (pt)
DK (1) DK1879560T3 (pt)
DO (1) DOP2006000100A (pt)
EA (1) EA200702344A1 (pt)
ES (1) ES2523663T3 (pt)
GT (1) GT200600183A (pt)
IL (1) IL186945A0 (pt)
MX (1) MX2007013779A (pt)
NO (1) NO20076187L (pt)
PE (1) PE20061414A1 (pt)
PL (1) PL1879560T3 (pt)
PT (1) PT1879560E (pt)
SI (1) SI1879560T1 (pt)
TW (1) TW200719902A (pt)
UY (1) UY29511A1 (pt)
WO (1) WO2006117139A2 (pt)
ZA (1) ZA200710418B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100704825B1 (ko) 2003-02-21 2007-04-09 바이엘 쉐링 파마 악티엔게젤샤프트 Ｕｖ 안정성 경피 치료 플라스터
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
WO2012031999A2 (en) 2010-09-06 2012-03-15 Bayer Pharma Aktiengesellschaft Low-dose transdermal patches with high drug release

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
EP0453396B1 (de) * 1990-03-30 1995-12-13 Ciba SC Holding AG Lackzusammensetzungen
US8173592B1 (en) * 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
EP1269999B1 (en) * 2000-03-17 2013-05-01 Hisamitsu Pharmaceutical Co. Inc. Ultraviolet-shielding patch
EP1452173A1 (de) * 2003-02-25 2004-09-01 Schering AG UV-stabiles transdermales Pflaster
KR100704825B1 (ko) 2003-02-21 2007-04-09 바이엘 쉐링 파마 악티엔게젤샤프트 Ｕｖ 안정성 경피 치료 플라스터
WO2005023878A1 (en) * 2003-09-11 2005-03-17 Ciba Specialty Chemicals Holding Inc. Water based concentrated product forms of light stabilizers made by a heterophase polymerization technique

Also Published As

Publication number Publication date
WO2006117139A2 (de) 2006-11-09
ZA200710418B (en) 2009-08-26
MX2007013779A (es) 2008-01-22
PL1879560T3 (pl) 2015-02-27
KR101426218B1 (ko) 2014-08-05
DOP2006000100A (es) 2007-01-31
IL186945A0 (en) 2008-02-09
KR101351161B1 (ko) 2014-01-14
WO2006117139A3 (de) 2007-04-19
JP5360877B2 (ja) 2013-12-04
UY29511A1 (es) 2006-08-31
CA2605112C (en) 2013-11-05
CA2605112A1 (en) 2006-11-09
CR9483A (es) 2008-01-21
TW200719902A (en) 2007-06-01
KR20130099203A (ko) 2013-09-05
GT200600183A (es) 2007-01-03
ES2523663T3 (es) 2014-11-28
AU2006243442A1 (en) 2006-11-09
DK1879560T3 (en) 2014-11-24
CN108969507A (zh) 2018-12-11
SI1879560T1 (sl) 2015-01-30
CY1115757T1 (el) 2017-01-25
BRPI0611087A2 (pt) 2010-08-03
JP2013177451A (ja) 2013-09-09
PT1879560E (pt) 2014-11-19
CN101171001A (zh) 2008-04-30
AR055927A1 (es) 2007-09-12
KR20080003854A (ko) 2008-01-08
PE20061414A1 (es) 2007-01-26
EP1879560B1 (de) 2014-08-27
EP1719504A1 (de) 2006-11-08
EP1879560A2 (de) 2008-01-23
JP2008540352A (ja) 2008-11-20
EA200702344A1 (ru) 2008-12-30

Similar Documents

Publication Publication Date Title
EP4196113A1 (en) Pharmaceutical compositions and methods for treating parkinson's disease
Yan et al. Dural afferents express acid-sensing ion channels: a role for decreased meningeal pH in migraine headache
Argyropoulos et al. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder
Oliveira et al. The antidepressant-like effect of physical activity on a voluntary running wheel
AR097045A2 (es) Sistema terapéutico transdérmico
HRP20050828B1 (hr) Uv-stabilni transdermalni flaster
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
NO20083104L (no) Fast preparat
BR0212026A (pt) Sistema terapêutico transdérmico com fentanila ou substâncias análogas
NO20076187L (no) Fast, transdermalt, terapeutisk system omfattende UV-absorber
JP2008517934A5 (pt)
Gomora et al. Mibefradil potently blocks ATP-activated K+ channels in adrenal cells
US20080233180A1 (en) Transdermal Patch and Method For Delivery Of Vitamin B12
Hadgraft et al. Passive transdermal drug delivery systems: recent considerations and advances
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
Zhang et al. Synaptophysin and the dopaminergic system in hippocampus are involved in the protective effect of rutin against trimethyltin-induced learning and memory impairment
Poretti et al. Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression
Liu et al. Potent inhibition of native TREK-1 K+ channels by selected dihydropyridine Ca2+ channel antagonists
Miyagishi et al. Cytoprotective effects of Hangekobokuto against corticosterone-induced cell death in HT22 cells
CL2013000709A1 (es) Composicion que contiene nifurtimox y un antihelmintico seleccionado de: pf1022, emopdepsido, tribendimidina, amidantel, bay d 9216, praziquantel o benzoato de bencilo; util en el tratamiento de enfermedades causadas por giardias (div. sol. 1577-10).
Hanon et al. Prevention of dementia and cerebroprotection with antihypertensive drugs
Hondebrink et al. High concentrations of MDMA (‘ecstasy’) and its metabolite MDA inhibit calcium influx and depolarization-evoked vesicular dopamine release in PC12 cells
WO2009007334A3 (de) Transdermale therapeutische systeme, welche den wirkstoff anastrozol enthalten
L Sulkowski et al. The future of D-cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders
Hosseini-Sharifabad et al. The effect of lead, restraint stress or their co-exposure on the movement disorders incidence in male mice

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application